Xilio Therapeutics, Inc. — Director's Dealing 2021

Nov 3, 2021

SEC Form 4/A — Form 4/A

Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-10-26

Reporting Person: SV7 Impact Medicine Fund LP (10% Owner)
Reporting Person: SV7 (IMF) GP LLP (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-26	Common Stock	C	998544	—	Acquired	998544	Direct
2021-10-26	Common Stock	C	998544	—	Acquired	998544	Indirect
2021-10-26	Common Stock	C	302588	—	Acquired	1301132	Direct
2021-10-26	Common Stock	C	302588	—	Acquired	1301132	Indirect
2021-10-26	Common Stock	P	312500	$16.00	Acquired	1613632	Direct
2021-10-26	Common Stock	P	312500	$16.00	Acquired	1613632	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-26	Series B Convertible Preferred Stock	$	C	9486166	Disposed		Common Stock (998544)	Direct
2021-10-26	Series B Convertible Preferred Stock	$	C	9486166	Disposed		Common Stock (998544)	Indirect
2021-10-26	Series C Convertible Preferred Stock	$	C	2874595	Disposed		Common Stock (302588)	Direct
2021-10-26	Series C Convertible Preferred Stock	$	C	2874595	Disposed		Common Stock (302588)	Indirect

Footnotes

F1: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date.

F2: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021.

F3: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom.

F4: This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering.